Joseph FOKAM1 ,Rodrigue KAMGA WOUAMBO2*, Philippe Salomon NGUWOH3, Christian TAHEU NGOUNOUH4 , Samuel FOSSO5 , Ester NJOM NLEND6 , Celine NKENFOU NGEFEU1
1Chantal Biya International Reference Center for HIV Prevention and Management, Yaounde, Cameroon ; 2IUES/INSAM/ISSAS: Estuary Academy and Strategic Institute, Higher Institut of Applied Health Science, University of Buea ; 3National Public Health Laboratory-Ministry of Public Health, Cameroon; 4Higher Institute of Sciences and Technics applied to Health, Yaounde; Cameroon ; 5Biosante international Laboratory ; 6Essos Hospital Center
CaHReF 2018, Yaoundé Congres hall, 08 – 11 January 2019 , OSME050
Background: In Cameroon, the high prevalence of HBV leads to systematic vaccination of new-born-babies. These efforts must be followed by a strict pediatric monitoring in order to evaluate the impact of these programmatic interventions previously done. In addition, with the high prevalence of the co-infection HIV/HBV of pregnant women
Objectif: The aim of this study was to evaluate the determinant of HBV among HIV positives children.
Methodology: A cross-sectional, prospective, descriptive study was held from April to June 2017 at Essos-Hospital-Center-Yaounde, Cameroon. ELISA-sandwich (HBsAg EIA-test-kit-Rapid Lab) was done on each duplicated samples and the mean of density was calculated. For p <0.05, the difference was statistically significant.
Results: 54.20% of the 83 HIV+ subjects were female. The mean age was 9years (IQR: 6-12(, with 48.2% aged (10-15(, which is situated after the age bracket of anti-VHB systematic vaccination-coverage in Cameroon. The prevalence of HBV among HIV-positives-children in this study was 2.41% (2/83). Those 2 children were from mother with an-unknown-HBV-status (p=0, 0097), were born through normal-way (p=0, 0018). In addition, those children of 11 and 15 years of age were not vaccinated, didnt receive anti-HBV-serum, hadnt been bathed with an antiseptic-solution-at-birth as recommended. However, all of them were full-breastfed. Maternal-exposition to the protocol tenofovir-lamivudine-efavirenz (TENLAM-E) during pregnancy
Conclusion/Recommandation: The prevalence of HBV in this study was low and the mother unknown HBV status during pregnancy was probably incrimated. So, to better protect children against HBV implies necessarily systematic vaccination, and the use-of-the protocol TENLAM-E by pregnant-women. The knowledge of HBV status by each mother, previous vaccinal-historic of children and full-bread-feeding should also be included.
Key Words: HBV-infection, Risk-factors, Children living